Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
ETFs with CMRX as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|0.36%||Wilshire Micro-Cap ETF (based on the Wilshire US Micro-Cap Ind (WMCR)||-1.57 (-5.54%)|
|0.33%||iShares Microcap ETF (IWC)||-4.32 (-5.38%)|
Company Description (as filed with the SEC)
Chimerix, Inc. is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals to address unmet medical needs. We were founded in 2000 based on the promise of our proprietary lipid conjugate technology to unlock the potential of some of the most broad-spectrum antivirals by enhancing their antiviral activity and safety profiles in convenient, orally administered dosing regimens. Based on our proprietary lipid conjugate technology, our lead compound, brincidofovir (BCV, CMX001), is in Phase 3 clinical development. In addition, we have an active discovery program focusing on viral targets for which limited or no therapies are currently available. Brincidofovir Phase 3 SUPPRESS Trial Brincidofovir is an investigational oral nucleotide analog that has shown broad-spectrum antiviral activity against all five families of dsDNA (double-stranded DNA) viruses that affect humans. ... More ...
Where does CMRX fit in the risk graph?
|Annual EPS Est:||$-1.8|
|Quarterly EPS Est:||-0.75|